Fig. 6.

Inhibition of in vivo tumor growth inhibition of breast and ovarian cancer by GSK3326595, niraparib, or the combination. A, Efficacy of GSK3326595, niraparib, or the combination in the MDA-MB-468 xenograft model. NSG mice bearing established MDA-MB-468 tumors were treated with either vehicle (0.5% methylcellulose), twice daily oral administration of GSK3326595 (50 mg/kg), once daily oral administration of niraparib (35 mg/kg), or the combination of both agents (n = 10). B, Efficacy of GSK3326595, niraparib, or the combination in the OVCAR3 xenograft model. CD.17 SCID mice bearing established OVCAR-3 tumors were treated with either vehicle, twice daily oral administration PRMT5i (50 mg/kg), once daily oral administration of niraparib (35 mg/kg), or the combination of both agents (n = 10). All error bars represent mean ± SEM and student t-test determined significance. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001